Literature DB >> 17186537

Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma.

Yao-Yuan Hsieh1, Cheng-Chun Lee, Chi-Chen Chang, Yu-Kuo Wang, Lian-Shun Yeh, Chich-Sheng Lin.   

Abstract

Endometriosis and leiomyoma display features similar to malignancy, requiring neovascularization to proliferation and growth. Altered vascular-related genes might be related to the development of endometriosis and leiomyoma. Polymorphisms of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) genes have been linked with some vascular diseases. This study investigates whether ACE I/D gene polymorphisms could be used as markers of susceptibility in endometriosis and leiomyoma. Women were divided into three groups: (1) endometriosis (n = 125); (2) leiomyoma (n = 120); (3) normal controls (n = 128). Genomic DNA was obtained from peripheral leukocyte. ACE I/D gene polymorphisms in intron 16 were amplified by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) Genotypes and allelic frequencies in both groups were compared. We observed the genotype distribution and allele frequency of ACE I/D gene polymorphisms in both groups were significantly different. Proportions of ACE*I homozygote/heterozygote/D homozygote in both groups were: (1) 50.4/24/25.6%; (2) 25/23.33/51.67%; (3) 10.2/29.7/60.1%. Proportions of I/D alleles in each group were: (1) 62.4/37.6%; (2) 36.7/63.3%; (3) 25/75%. We concluded that ACE*I/D gene polymorphisms are associated with endometriosis and leiomyoma susceptibilities. ACE*I-related genotypes and allele are strongly related to the occurrence of endometriosis and moderately related to the occurrence of leiomyoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186537     DOI: 10.1002/mrd.20474

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  7 in total

1.  Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.

Authors:  Nicole M Fischer; Tim O Nieuwenhuis; Bhuchitra Singh; Gayane Yenokyan; James H Segars
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

2.  Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?

Authors:  Hemant Kumar Bid; Parmeet Kaur Manchanda; Rituraj Konwar; Kasif Hanif; V Laxman Nayak; Vishwajeet Singh
Journal:  Indian J Urol       Date:  2010-10

Review 3.  Functional genetic polymorphisms and female reproductive disorders: part II--endometriosis.

Authors:  C B Tempfer; M Simoni; B Destenaves; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2008-09-19       Impact factor: 15.610

4.  Co-existence of benign gynecological tumors with endometriosis in a group of 1,000 women.

Authors:  Charoula Matalliotaki; Michail Matalliotakis; Panagiotis Ieromonachou; George N Goulielmos; Maria I Zervou; Aggelos Laliotis; Demetrios A Spandidos; Aydin Arici; Ioannis Matalliotakis
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

5.  Association of ACE I/D and AGTR1 A1166C Gene Polymorphisms and Risk of Uterine Leiomyoma: A Case-Control Study.

Authors:  Farshid Keshavarzi; Batool Teimoori; Farahnaz Farzaneh; Mojgan Mokhtari; Darya Najafi; Saeedeh Salimi
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

6.  Interaction with angiotensin-converting enzyme-encoding gene in female infertility: Insertion and deletion polymorphism studies.

Authors:  Johara Al-Mutawa
Journal:  Saudi J Biol Sci       Date:  2016-06-18       Impact factor: 4.219

7.  Epidemiological aspects of the outcomes from the treatment of endometriosis: Experience from two different geographical areas.

Authors:  Charoula Matalliotaki; Michail Matalliotakis; Maria I Zervou; Athina Patelarou; Ioannis Koliarakis; Demetrios A Spandidos; Aydin Arici; Ioannis Matalliotakis; George N Goulielmos
Journal:  Exp Ther Med       Date:  2019-12-05       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.